ArticleScientific reports2019
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.Annals of hematology · 2020Trial
- Identification and Management of Differentiation Syndrome in Emergency Settings: A Narrative Review.Cancers · 2026Review
- Predictors and kinetics of ATO-induced leukocytosis in acute promyelocytic leukemia patients: a retrospective study.Discover oncology · 2026Article
- Dynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia.Frontiers in oncology · 2026Article
- The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia.Frontiers in pharmacology · 2025Article
- Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them.Cancers · 2024Review
- Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide.Annals of hematology · 2024Review
- Review
- Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.BMC cancer · 2023Article
- The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.Frontiers in oncology · 2022Article
- Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT.Journal of oncology · 2021Article
- Differentiation Syndrome, a Side Effect From the Therapy of Acute Promyelocytic Leukemia.Cureus · 2020Article
- Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with AsArchives of toxicology · 2020Article
- The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is generally held to have favorable risk, but we have observed a high incidence of early deaths caused by fatal bleeding and differentiation syndrome (DS). We retrospectively analyzed 259 APL patients from 2002 to 2014 who all received all-trans retinoic acid (ATRA) with the support of sufficient transfusions, followed by 4 days of idarubicin. High-risk status was determined as a diagnostic leukocyte count (WBCdx) >10 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.